evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 80%Moderate 0 · 0%High 0 · 0%

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

Depressive symptoms · treatment‐resistant depression in adults

Switching to mianserin (60 mg/d) showed no clear difference in depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).

1 finding from 1 review

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

Leaving the study early · treatment‐resistant depression in adults

Switching to mianserin (60 mg/d) showed no clear difference in dropouts compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).

1 finding from 1 review

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

Response (> 50% improvement on 29‐item HAM‐D SIGH‐SAD) · treatment‐resistant depression in adults

Switching to mianserin (60 mg/d) showed no clear difference in response (≥ 50% improvement in HAM‐D score) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).

1 finding from 1 review

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

Remission (HAM‐D total score ≤ 8) · treatment‐resistant depression in adults

Switching to mianserin (60 mg/d) showed no clear difference in remission (HAM‐D total score ≤ 8) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).

1 finding from 1 review